Cystic Fibrosis Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Cystic Fibrosis Market
The cystic fibrosis market size was valued at USD 5.12 billion in 2019, and the market is now projected to grow from USD 62.57 billion by 2032, exhibiting a CAGR of 20.1% during the forecast period of 2020-2027.
The COVID-19 pandemic affects cystic fibrosis (CF) disease because patients with CF are vulnerable to the development of various lung-associated problems and diabetes due to the disease. The virus directly impacts the cystic fibrosis market growth. The ECFS, one of the organizations concerned is closely evaluating the data gathered from the Patient Registry to determine the actual effect of COVID-19 on people with CF. Strategies to promote data sharing with National CF registries seek to find out factors that would determine the worsening of the disease. This improves CF patient management and treatment through this data analysis approach.
The cystic fibrosis market share is attributed to the rising rate of occurrence of the genetic disorder-cystic fibrosis that affects more than 70,000 people around the globe. Around 1000 new cases annually are identified, implying the need for respiratory, gastrointestinal and reproductive treatment approaches. Developments in diagnostic capabilities permit early identification, boosting the availability of appropriate cures. This trend is favourable for the improvement of the conditions for patients and helps the market to strengthen. The increase in the number of patients with CF is the rationale for the steady advancement in treating the disease.
Further, the increasing number of cystic fibrosis (CF) cases contributes to improving the treatment sector's pharmacotherapy direction and the positive trends of the market. Large firms are paying concentration to pipeline candidates that aim at the CFTR protein defects. The new drugs such as Ivacaftor/Lumacaftor have eased the care provision greatly as the patient prognosis improves. Advances in research and development and technology are spurring new product development in the form of product innovations. These are some of the advancements opening up the market and the status of those diagnosed with cystic fibrosis.
Comprehensive Analysis of Cystic Fibrosis Market
The cystic fibrosis market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by drug class, by route of administration and by distribution channel. The drug class includes Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement and Others. The route of administration includes, Oral and Parenteral. The distribution channel includes, Retail Pharmacies & Drug Stores, Online Pharmacies and Hospital Pharmacies.
North America was the largest CAGR in the cystic fibrosis market valued at USD 3.89 billion in 2019. They also provided data suggesting North America should remain the global market leader. The factors responsible for strengthening the market in certain regions are an increase in cases of CF, several patients suffering from various respiratory diseases affecting CF, enhancement in research and development activities, a rise in healthcare expenditures and so on.
The top market players play a crucial role in the healthcare industry, assuring industrial prospectus growth and setting market standards. These players include Vertex Pharmaceuticals Incorporated, AbbVie Inc., Novartis AG, Gilead Sciences, Inc., Mylan N.V., Pfizer Inc., Bayer AG, Genentech, Inc., AstraZeneca and others. These market players provide a level-playing competitive landscape.
In October 2019, AbbVie Inc. revealed its partnership with the Cystic Fibrosis Foundation to advance the CFTR potentiator compound obtained from the foundation.
Segmentation Table
Global Cystic Fibrosis Market Scope
Study Period2019-2027
Base Year2019
Forecast Period2020-2027
Growth RateCAGR of 20.1% from 2020 to 2027
Historical Period2016-2018
UnitValue (USD Billion)
SegmentationBy Drug Class, Route of Administration, Distribution Channel, and Region
By Drug ClassCystic Fibrosis Transmembrane Conductance Regulator (CFTR)
Bronchodilators
Mucolytic
Pancreatic Enzyme Supplement
Others
By Route of AdministrationOral
Parenteral
By Distribution ChannelRetail Pharmacies & Drug Stores
Online Pharmacies
Hospital Pharmacies
By RegionNorth America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
Rest of the World
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. New Product Launches
- 4.2. Prevalence of Cystic Fibrosis
- 4.3. Pipeline Analysis
- 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
- 5. Global Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class
- 5.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
- 5.2.2. Bronchodilators
- 5.2.3. Mucolytic
- 5.2.4. Pancreatic Enzyme Supplement
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast – By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies & Drug Stores
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia pacific
- 5.5.4. Rest of the World
- 6. North America Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Drug Class
- 6.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
- 6.2.2. Bronchodilators
- 6.2.3. Mucolytic
- 6.2.4. Pancreatic Enzyme Supplement
- 6.2.5. Others
- 6.3. Market Analysis – By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.4. Market Analysis – By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies & Drug Stores
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Drug Class
- 7.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
- 7.2.2. Bronchodilators
- 7.2.3. Mucolytic
- 7.2.4. Pancreatic Enzyme Supplement
- 7.2.5. Others
- 7.3. Market Analysis – By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.4. Market Analysis – By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies & Drug Stores
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis – By Country/ sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia pacific Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Drug Class
- 8.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
- 8.2.2. Bronchodilators
- 8.2.3. Mucolytic
- 8.2.4. Pancreatic Enzyme Supplement
- 8.2.5. Others
- 8.3. Market Analysis – By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.4. Market Analysis – By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies & Drug Stores
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis – By Country/ sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Rest of the World Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Drug Class
- 9.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
- 9.2.2. Bronchodilators
- 9.2.3. Mucolytic
- 9.2.4. Pancreatic Enzyme Supplement
- 9.2.5. Others
- 9.3. Market Analysis – By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.4. Market Analysis – By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail Pharmacies & Drug Stores
- 9.4.3. Online Pharmacies
- 10. Cystic Fibrosis Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Drug Class
- 10.2.1. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
- 10.2.2. Bronchodilators
- 10.2.3. Mucolytic
- 10.2.4. Pancreatic Enzyme Supplement
- 10.2.5. Others
- 10.3. Market Analysis – By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.4. Market Analysis – By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies & Drug Stores
- 10.4.3. Online Pharmacies
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2019)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis – Major Players
- 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.5.1. Vertex Pharmaceuticals Incorporated
- 11.5.1.1. Overview,
- 11.5.1.2. Products & services,
- 11.5.1.3. SWOT analysis,
- 11.5.1.4. Recent developments,
- 11.5.1.5. strategies,
- 11.5.1.6. financials (based on availability)
- 11.5.2. AbbVie Inc.
- 11.5.2.1. Overview,
- 11.5.2.2. Products & services,
- 11.5.2.3. SWOT analysis,
- 11.5.2.4. Recent developments,
- 11.5.2.5. strategies,
- 11.5.2.6. financials (based on availability)
- 11.5.3. Novartis AG
- 11.5.3.1. Overview,
- 11.5.3.2. Products & services,
- 11.5.3.3. SWOT analysis,
- 11.5.3.4. Recent developments,
- 11.5.3.5. strategies,
- 11.5.3.6. financials (based on availability)
- 11.5.4. Gilead Sciences, Inc.
- 11.5.4.1. Overview,
- 11.5.4.2. Products & services,
- 11.5.4.3. SWOT analysis,
- 11.5.4.4. Recent developments,
- 11.5.4.5. strategies,
- 11.5.4.6. financials (based on availability)
- 11.5.5. Mylan N.V.
- 11.5.5.1. Overview,
- 11.5.5.2. Products & services,
- 11.5.5.3. SWOT analysis,
- 11.5.5.4. Recent developments,
- 11.5.5.5. strategies,
- 11.5.5.6. financials (based on availability)
- 11.5.6. Pfizer Inc.
- 11.5.6.1. Overview,
- 11.5.6.2. Products & services,
- 11.5.6.3. SWOT analysis,
- 11.5.6.4. Recent developments,
- 11.5.6.5. strategies,
- 11.5.6.6. financials (based on availability)
- 11.5.7. Bayer AG
- 11.5.7.1. Overview,
- 11.5.7.2. Products & services,
- 11.5.7.3. SWOT analysis,
- 11.5.7.4. Recent developments,
- 11.5.7.5. strategies,
- 11.5.7.6. financials (based on availability)
- 11.5.8. Genentech, Inc.
- 11.5.8.1. Overview,
- 11.5.8.2. Products & services,
- 11.5.8.3. SWOT analysis,
- 11.5.8.4. Recent developments,
- 11.5.8.5. strategies,
- 11.5.8.6. financials (based on availability)
- 11.5.9. AstraZeneca
- 11.5.9.1. Overview,
- 11.5.9.2. Products & services,
- 11.5.9.3. SWOT analysis,
- 11.5.9.4. Recent developments,
- 11.5.9.5. strategies,
- 11.5.9.6. financials (based on availability)
- 11.5.10. Other Prominent Market Players
- 11.5.10.1. Overview,
- 11.5.10.2. Products & services,
- 11.5.10.3. SWOT analysis,
- 11.5.10.4. Recent developments,
- 11.5.10.5. strategies,
- 11.5.10.6. financials (based on availability)
- 12. Strategic Recommendations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook